NEW YORK, NY / ACCESSWIRE / December 2, 2019 / Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced that it will be presenting at the 12th annual LD Micro Main Event on Tuesday, December 10th at 3:00 PM PST / 6:00 PM EST. Mr. Robb Knie, Chief Executive Officer, will be presenting and meeting with investors.
The LD Micro Main Event will take place on December 10th-12th in Los Angeles, at the Luxe Sunset Bel Air Hotel, which will feature 275 companies, and will be attended by over 1,400 individuals.
View Hoth Therapeutics's profile here: http://www.ldmicro.com/profile/HOTH.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, and acne. HOTH has the exclusive worldwide rights to BioLexa, the company's proprietary lead drug candidate topical platform that uniquely combines two FDA approved compounds to fight bacterial infections across multiple indications. HOTH is preparing to launch its clinical trial for the treatment of adolescent subjects, 2-17 years of age, with mild to moderate atopic dermatitis during 2020. To learn more, please visit www.hoththerapeutics.com.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.
What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.
KCSA Strategic Communications
Valter Pinto / Daniela Guerrero
(212) 896-1254 / (212) 682-6300
SOURCE: Hoth Therapeutics via LD Micro